iShares 10 20 Year Treasury Bond ETF vs GeneDx Holdings Corp — how do they compare? iShares 10 20 Year Treasury Bond ETF trades at $92.07 (market cap $11.02B), while GeneDx Holdings Corp trades at $68.16 (market cap $2.02B). The key difference: iShares 10 20 Year Treasury Bond ETF is far larger — about 5.5× GeneDx Holdings Corp's market cap, and GeneDx Holdings Corp is trading nearer its 52-week high, iShares 10 20 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| TLH | WGS | |
|---|---|---|
Market Cap | $11.02B | $2.02B |
Volume | 6,609,157 | 734,640 |
Sector | Fixed Income | Health |
52-Week High | $105.36 | $167.51 |
52-Week Low | $91.34 | $34.51 |
Typical Hold Time | — | 19 Days |
Enterprise Value | — | $2.05B |
Signals from Pluang's Aura AI — not financial advice
TLH, the iShares 10-20 Year Treasury Bond ETF, trades at $91.45, down 0.12% with a bearish technical outlook. The ETF has seen unusually high trading volume recently, with 2.3 million shares traded on September 30, 2026. Bond market volatility has driven significant price movements as 10-year Treasury yields reached multi-decade highs above 5% before pulling back. The fund maintains regular dividend distributions, with recent payments ranging from $0.36 to $0.38 per share.
The outlook remains challenging amid persistent bond market volatility and expectations of higher-for-longer interest rates. Rising yields pressure bond prices, creating headwinds for TLH, though current levels may attract income-seeking investors. Key risks include further Fed tightening and inflation concerns, while potential catalysts include economic slowdown or Fed policy shifts.
GeneDx (WGS) trades at $68.50, down 0.04% with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue of $114.4M beating expectations but net income margin remains negative at -23.4%. Recent developments include new product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus targets $81.00 (18% upside), fundamental challenges persist with negative profitability metrics and high valuation multiples. The stock faces execution risks amid competitive genomics landscape, but operational improvements and testing volume growth provide potential catalysts for recovery.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
TLH tracks the ICE U.S. Treasury 10-20 Year Bond Index, offering targeted exposure to intermediate-to-long term government debt. It serves as a middle ground between the 7-10 year (IEF) and 20+ year (TLT) ETFs, balancing yield and duration risk.
Read more on TLH →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →